Press release

Conformity of the first industrial transposition batch of Zeneo® Hydrocortisone

First milestone achieved in the relationship with Eton Pharmaceuticals

Dijon, 21 March 2022

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing and soon to market a portfolio of drugs for use in emergency situations, announces the compliance with specifications of the first industrial transposition batch of ZENEO® Hydrocortisone (acute adrenal crisis).

Patrick Alexandre, Chairman of the Crossject Management Board, said: "*In recent months, we have been proud to announce successive key events in our development, notably the commercial agreement with Eton Pharmaceuticals in June 2021 and the validation of the ZENEO® Midazolam clinical batch at the end of 2021. Today, the compliance of the ZENEO® Hydrocortisone industrial transposition batch is a further source of great satisfaction for Crossject. This step allows us to bring forward the next steps in the drug's development program, achieve a milestone in our contractual relationship with Eton Pharmaceuticals and provide further illustration of our industrial excellence.*"

All tests performed on the ZENEO® Hydrocortisone batch, produced at the end of 2021, show it to be compliant with the industrial transposition specifications This phase, which is fundamental to the preparation of marketing authorisation (MA) files in the United States and Europe, aims to prove that the drug's formula and manufacturing processes can be transposed to industrial scale. This allows Crossject to launch the production of three validation batches and to undertake a bioequivalence study. After the successive industrial transpositions carried out for Midazolam and Epinephrine[1] in 2021, this news provides further proof of the maturity of Crossject's industrial facilities.

The achievement of this milestone backs up Crossject's aim of filing its marketing authorization

[1] Epinephrine is the name used for Adrenaline in the US.

application for ZENEO® Hydrocortisone in 2023.

It also triggers a contractual milestone payment of $0.5 million in addition to the $0.5 million Crossject received when the agreement with Eton Pharmaceuticals was signed in June 2021. As a reminder, the exclusive licensing, distribution and promotion agreement with Eton Pharmaceuticals for the United States and Canada provides for the payment of a total of $5 million in the lead-up to the commercial launch of ZENEO® Hydrocortisone. In the commercial phase, Crossject will receive a price for each product supplied, as well as royalties.[2] Eton Pharmaceuticals is responsible for all regulatory and commercial activities, including marketing authorisation filings, regulatory filing fees, distribution and promotion. Crossject is responsible for development activities, including clinical development and manufacturing.

Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Christelle Distinguin +33 (0)3 80 43 54 89
christelle.distinguin@buzzetcompagnie.com

About CROSSJECT • www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, acute adrenal insufficiency, allergic shock, asthma attack, overdose, severe migraine, etc. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.

[2] See press release dated 15 June 2021.